Kim Schafer, NP
Family · Sacramento, CANPI 1912957291
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 55.3% of the total. 2025 is the largest year on record at $77,912, 2.1 times the $37,973 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $748.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$159K
- Sanofi$41K
- CSL Behring$18K
- Pfizer$16K
- Bayer$14K
- Genentech USA, Inc.$11K
- plus $28K from 7 others
What the payments were for
- Consulting fees$57,63320%
- Speaking & faculty fees$158,27255%
- Travel & lodging$62,69022%
- Food & beverage$9,1143%
- Education$4350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 157 | $159,234 |
| Sanofi | 64 | $41,148 |
| CSL Behring | 36 | $18,106 |
| Pfizer | 25 | $16,312 |
| Bayer | 20 | $14,441 |
| Genentech USA, Inc. | 30 | $10,693 |
| HEMA Biologics, LLC | 20 | $7,905 |
| Sanofi US Services Inc. | 1 | $7,380 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $5,357 |
| Biomarin Pharmaceutical Inc. | 8 | $3,840 |
| Spark Therapeutics, Inc. | 6 | $3,269 |
| Genentech, Inc. | 5 | $306 |
| Octapharma USA, Inc. | 2 | $153 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$288,144 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 14 | $142,764 |
Paid to pharmacies, not to this prescriber.
Other family in Sacramento
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
- Pamela ScottVisalia$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.